JP2004534850A - 強力な選択的メラノコルチン−４受容体アゴニストとしての環状ペプチド - Google Patents

強力な選択的メラノコルチン−４受容体アゴニストとしての環状ペプチド Download PDF

Info

Publication number
JP2004534850A
JP2004534850A JP2003512363A JP2003512363A JP2004534850A JP 2004534850 A JP2004534850 A JP 2004534850A JP 2003512363 A JP2003512363 A JP 2003512363A JP 2003512363 A JP2003512363 A JP 2003512363A JP 2004534850 A JP2004534850 A JP 2004534850A
Authority
JP
Japan
Prior art keywords
compound according
receptor
administration
melanocortin
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003512363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534850A5 (enExample
Inventor
ベドナレク，マリア・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2004534850A publication Critical patent/JP2004534850A/ja
Publication of JP2004534850A5 publication Critical patent/JP2004534850A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003512363A 2001-07-12 2002-07-08 強力な選択的メラノコルチン−４受容体アゴニストとしての環状ペプチド Withdrawn JP2004534850A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30495801P 2001-07-12 2001-07-12
PCT/US2002/021443 WO2003006604A2 (en) 2001-07-12 2002-07-08 Cyclic peptides as potent and selective melanocortin-4 receptor agonists

Publications (2)

Publication Number Publication Date
JP2004534850A true JP2004534850A (ja) 2004-11-18
JP2004534850A5 JP2004534850A5 (enExample) 2005-12-22

Family

ID=23178678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003512363A Withdrawn JP2004534850A (ja) 2001-07-12 2002-07-08 強力な選択的メラノコルチン−４受容体アゴニストとしての環状ペプチド

Country Status (5)

Country Link
US (1) US6960646B2 (enExample)
EP (1) EP1409521A2 (enExample)
JP (1) JP2004534850A (enExample)
CA (1) CA2453027A1 (enExample)
WO (1) WO2003006604A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509912A (ja) * 2005-06-03 2009-03-12 アミカス セラピューティックス インコーポレイテッド 肥満を治療するための薬理学的シャぺロン

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
MXPA05013951A (es) * 2003-06-19 2006-02-24 Lilly Co Eli Agonsita del receptor de la melanocortina 4 (mc4) y sus usos.
EP1694348A4 (en) * 2003-12-10 2009-07-01 Merck & Co Inc INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN-4-RECEPTOR AGONISTS
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2006129317A1 (en) * 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem BACKBONE CYCLIZED MELANOCORTIN STIMULATING HORMONE (α S ) ANALOGS
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
MX2010013436A (es) 2008-06-09 2011-06-21 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de disfuncion sexual.
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
NZ596617A (en) 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
KR20120102716A (ko) 2009-11-23 2012-09-18 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴-1 수용체 특이적 선형 펩티드
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622860A (en) * 1994-02-17 1997-04-22 The Regents Of The University Of Michigan Genes encoding melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
CA2251520C (en) * 1997-10-31 2003-12-30 Atsushi Ohta Pipe connector connection checking assembly
HRP20030126B1 (en) * 2000-08-30 2009-01-31 F. Hoffmann - La Roche Ag Selective cyclic peptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509912A (ja) * 2005-06-03 2009-03-12 アミカス セラピューティックス インコーポレイテッド 肥満を治療するための薬理学的シャぺロン
JP2013067626A (ja) * 2005-06-03 2013-04-18 Amicus Therapeutics Inc 肥満を治療するための薬理学的シャペロン
US9381194B2 (en) 2005-06-03 2016-07-05 Amicus Therapeutics, Inc. Pharmacological chaperones for treating obesity
US9937165B2 (en) 2005-06-03 2018-04-10 Amicus Therapeutics, Inc. Pharmacological chaperones for treating obesity

Also Published As

Publication number Publication date
WO2003006604A3 (en) 2003-10-02
CA2453027A1 (en) 2003-01-23
US20040171793A1 (en) 2004-09-02
WO2003006604A2 (en) 2003-01-23
US6960646B2 (en) 2005-11-01
EP1409521A2 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
JP2004534850A (ja) 強力な選択的メラノコルチン−４受容体アゴニストとしての環状ペプチド
US6693165B2 (en) Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
DE69637430T2 (de) Neue opioid peptide, selektiv für kappa rezeptor
DE60038734T2 (de) Melanocortinrezeptor-liganden
US7795378B2 (en) Peptide compositions for treatment of sexual dysfunction
AU2009257631B2 (en) Melanocortin receptor-specific peptides for treatment of sexual dysfunction
JP2004534851A (ja) メラノコルチン受容体に特異的な線状および環状ペプチド
US20100121027A1 (en) Cyclic Peptide Compositions for Treatment of Sexual Dysfunction
KR20020081466A (ko) 펩티드 유도체
US5811400A (en) Peptide derivatives with δ opioid receptor antagonist or mixed μ agδ antagonist effects
JP2003501443A (ja) ニューロメジンｂおよびソマトスタチンレセプターアゴニスト
US8247530B2 (en) N-alkylated cyclic peptide melanocortin agonists
CA3168293A1 (en) Cyclotides in combination with kappa opioid receptor ligands for ms therapy
IL295151A (en) Diamine-linked receptor-specific cyclic peptides
US20060104907A1 (en) Biologically potent analogues of the Dmt-Tic pharmacophore and methods of use
RS56604B1 (sr) Agonisti vazopresinskog-2 receptora
Derdowska et al. New analogues of bradykinin containing a conformationally restricted dipeptide fragment in their molecules: Authors' affiliations
KR20020038400A (ko) 디썰파이드로 결합되는 환펩타이드형 화합물
RS54095B1 (sr) Visoko potentni potpuni i delimični agonisti i antagonisti nociceptinskih/orfaninskih fq receptora
KR20020038401A (ko) 멜라노코틴 수용체에 작용하는 트리펩타이드형 화합물
KR20020038398A (ko) 헵타펩타이드형 화합물 및 그 제조방법
KR20020038402A (ko) 멜라노코틴 수용체에 작용하는 테트라펩타이드형 화합물
KR20020038399A (ko) 멜라노코틴 수용체에 작용하는 락탐 결합으로 이루어진환펩타이드형 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050415

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070219